New CAR-T therapy targets tough T-Cell cancers in early trial
NCT ID NCT06874946
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new type of CAR-T cell therapy that targets a protein called CD5 on cancer cells. It is for people with T-cell acute lymphoblastic leukemia or T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: first, finding the safest dose, then testing how well it works in 30 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD5-targeted CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat T-cell cancers that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact